Treatment of drug-resistant pneumococcal pneumonia

Lancet Infectious Diseases

Volumn 2, Issue 7, 2002, Pages 404-415

  Garau, Javier ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL MÚTUA DE TERRASSA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CARBAPENEM DERIVATIVE; CEFPODOXIME; CEFPROZIL; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GATIFLOXACIN; GLYCOPEPTIDE; IMIPENEM; LEVOFLOXACIN; MACROLIDE; MEROPENEM; MOXIFLOXACIN; PENICILLIN DERIVATIVE; PENICILLIN G; PROCAINE PENICILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; TELITHROMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CALCULATION; HOSPITALIZATION; HUMAN; LOBAR PNEUMONIA; MINIMUM INHIBITORY CONCENTRATION; OUTPATIENT; PENICILLIN RESISTANCE; PHARMACODYNAMICS; PREVALENCE; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE;

EID: 0036288171     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(02)00316-X     Document Type: Review

References (134)

1. Impact of antibiotic resistance on chemotherapy for pneumococcal infections
2. Measuring the comparative efficacy of antibacterial agents for acute otitis media: The "Pollyana phenomenon"
3. Pneumococcal bacteremia with special reference to bacteraemic pneumococcal pneumonia
4. Penicillin-binding proteins in B-lactam resistant Streptococcus pneumoniae
5. A biological price of antibiotic resistance: Major changes in the peptidoglycan structure of penicillin-resistant pneumococci
6. Inhibition of the expression of penicillin resistance in Streptococcus pneumoniae by inactivation of cell wall muropeptide branching genes
7. Activities of oral and parenteral agents against penicillin-susceptible and resistant pneumococci
8. Treatment of pneumococcal pneumonia
9. Distribution of streptococcus pneumoniae resistant to penicillin in the USA and in vitro susceptibility to selected oral antibiotics
10. Susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to cefditoren and provisional interpretative criteria
11. The epidemiology of penicillin resistance in Streptococcus pneumoniae
12. Survey of susceptibilites of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolates to 26 antimicrobial agents: A prospective US study
13. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 US surveillance study
14. Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) study
15. The Alexander Project 1999 preliminary results: Penicillin and macrolide resistance in S pneumoniae from Europe
16. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-1998
17. Antimicrobial resistance in 1113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: Results of a 1-year (1996-1997) multicenter study
18. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994-1995: Results of a 30-center national surveillance study
19. Antimicrobial resistance in Streptococcus pneumoniae: An overview
20. Antimicrobial activities of beta-lactam antibiotics against penicillin-susceptible and penicillin-resistant pneumococci
21. Emergence in France of multiple clones of clinical Streptococcus pneumoniae isolates with high level resistance to amoxicillin
22. Trends in antibiotic resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain
23. Predictive factors for invasive disease due to penicillin-resistant Streptococcus pneumoniae: A population-based study
24. The Canadian bacterial surveillance network. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
25. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibiotic dosing of mice and men
26. Efficacy of high dose amoxicillin-clavulanate against experimental tract infections caused by strains of Streptococcus pneumoniae
27. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain
28. Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease
29. Penicillin-resistant pneumococci and community-acquired pneumonia
30. Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae
31. Clinical presentation, outcome, cost and risk factors associated with invasive Streptococcus pneumoniae infections in a pediatric population: A case-control study
32. Pneumonia caused by penicillin-non susceptible and penicillin-susceptible pneumococci in adults; a case-control study
33. Relationship between capsular type, penicillin susceptibility, and virulence of human Streptococcus pneumoniae isolates in mice
34. Clinical outcomes of bacteraemic pneumococcal pneumonia in the era of antibiotic resistance
35. Impact of penicillin resistance in community-acquired pneumococcal pneumonia in adults hospitalised patients: Findings of a French national prospective survey
36. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997
37. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence
38. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteraemic pneumococcal pneumonia
39. Comparative efficacy and safety of pharmacokinetically enchanced amoxicillin/clavulanate 2000/125 mg bd versus amoxicillin/clavulanate 875/125 mg tds in community-acquired pneumonia
40. Bacteraemic pneumococcal pneumonia in one American city: A 20 year longitudinal study, 1978-1997
41. Survival of bacteraemic pneumococcal pneumonia in Toronto, Ontario 1995-1998
42. Prospective study of prognostic factors in community-acquired bacteraemic pneumococcal pneumonia in five countries
43. Association between FcγRIIa-R131 allotype and bacteraemic pneumococcal pneumonia
44. Pneumococcus resistant to erythromycin and lincomycin
45. MefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae
46. Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin resistance in isolates of Streptococcus pneumoniae
47. Patterns of macrolide resistance determinants among community-acquired Streptococcus pneumoniae isolates over a 5-year period of decreased macrolide susceptibility rates
48. Antibiotic resistance in Streptococcus pneumoniae in Spain: An overview of the 1990s
49. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995
50. Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage
51. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from eastern Europe and North America
52. Mutation of 23S rRNA responsible for resistance to 16-membered macrolides and streptogramins in Streptococcus pneumoniae
53. Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 pneumococci from 10 central and eastern European countries
54. Extremely high incidence of macrolide and trimethroprim-sulfamethoxazole resistance among clinical isolates of Streptococcus pneumoniae in Taiwan
55. Macrolide resistance among invasive Streptococcus pneumoniae isolates
56. Pneumococcal macrolide resistance - Not a myth
57. Antimicrobial use and the emergence of antimicrobial resistance with S pneumoniae in the United States
58. Comparison of pharmacodynamics of azythromycin and erythromycin in vitro and in vivo
59. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections
60. Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia
61. Efficacies of ABT-773 and azithromycin against experimental rat lung infections caused by Streptococcus pneumoniae
62. Efficacy of ABT-773 against experimental bacteremia in mice caused by resistant Streptococcus pneumoniae
63. In vivo antibacterial activity of CP-654, 743, a new C2-Fluoro ketolide, against macrolide-resistant pneumococci and Haemophilus influenzae
64. Pneumococcal meningitis during therapy of otitis media with clarithromycin
65. Breakthrough sepsis in macrolide-resistant pneumococcal infection
66. Bacteraemic pneumonia due to multiresistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin
67. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin
68. Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy
69. Failure of macrolide therapy in patients with bacteremia due to macrolide-resistant Streptococcus pneumoniae
70. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin resistant Streptococcus pneumoniae
71. Emergence of macrolide resistance during treatment of pneumococcal pneumonia
72. Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3467 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents
73. Telithromycin is highly effective in the treatment of community-acquired respiratory tract infections caused by Streptococcus pneumoniae with reduced penicillin and/or macrolide susceptibility
74. Primary targets of fluoroquinolones in Streptococcus pneumoniae
75. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro
76. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae
77. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae
78. Characterisation of a mutation in the pare gene that confers fluoroquinolone resistance in Streptococcus pneumoniae
79. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae
80. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: Contributions of type II topoisomerase mutations and efflux to levels of resistance
81. Prevalence of gyrA, gyrB, parC, and pare mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season
82. Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolates in the United States in 1992 to 1996 and 1999 to 2000
83. Combinations of QRDR mutations and efflux causing cross-resistance among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae
84. Prevalence of gyrA, gyrB, parC, and pare mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during 1997-1998 respiratory season
85. In vitro exchange of fluoroquinolone resistance determinants between Streptococcus pneumoniae and viridans streptococci and genomic organization of the parE-parC region in S. mitis
86. Horizontal transfer contributes minimally to fluoroquinolone resistance in pneumococci
87. Prevalence of resistance to fluoroquinolones in clinical isolates of Streptococcus pneumoniae
88. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones in the United States
89. Decrease in susceptibility to moxifloxacin and plifloxacin of Streptococcus pneumoniae isolated from sinus aspirates during two periods
90. Ciprofloxacin resistance among respiratory pneumococcal strains in Spain
91. Antimicrobial susceptibilities of 1684 Streptococcus pneumoniae and 2039 Streptococus pyogenes isolates and their ecological relationships: Results of a 1 year (1998-1999) multicenter surveillance study in Spain
92. Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland
93. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: Results of a Hong Kong multicentre study in 2000
94. Clonal diffusion of multiresistant pneumococcal strains showing high level of quinolone resistance in the North of Spain
95. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: A case-control study
96. Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin
97. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae
98. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respirtory tract infections
99. Comparative in vitro potency of gemifloxacin against european respiratory tract pathogens isolated in the Alexander Project
100. Antipneumococcal activities of gemifloxacin compared to those of nine other agents
101. In vitro selection of resistance to gemifloxacin, trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae
102. In vitro and in vivo antimicrobial activities of T3811ME a novel des-F(6)quinolone
103. a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci
104. Ciprofloxacin in acute exacerbations of chronic bronchitis
105. Pneumococcal bacteremia during ciprofloxacin therapy for pneumococcal pneumonia
106. Pneumococcal meningitis during intravenous ciprofloxacin therapy
107. Inappropriate use of oral ciprofloxacin
108. Infectious complications with respiratory pathogens despite ciprofloxacin therapy
109. Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin
110. Superinfection with Streptococcus pneumoniae during therapy with ciprofloxacin
111. Fatal meningitis due to levofloxacin-resistant Streptococcus pneumoniae
112. Reply. Levofloxacin-resistant pneumococcus
113. Fluoroquinolone resistance in Streptococcus pneumoniae
114. Three levofloxacin treatment failures of pneumococcal respiratory tract infections
115. Epidemiology and clinical outcomes of patients with levofloxacin resistant pneumococcus
116. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia
117. Levofloxacin treatment failure of pneumococcal pneumonia and development of resistance during therapy
118. Levofloxacin-resistant pneumococcus
119. Will pneumococci put quinolones in their place
120. A prediction rule to identify low-risk patients with community-acquired pneumonia
121. Management of community-acquired pneumonia in the era of pneumococcal resistance
122. Practice guidelines for the management of community-acquired pneumonia
123. Assessing the quality of the Alexander Project
124. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia
125. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia
126. Efficacy and safety of moxifloxacin versus clarithromycin for community-acquired pneumonia
127. Clinical efficacy and safety of a new fluoroquinolone, Gatifloxacin, for the treatment of S. pneumoniae community acquired pneumonia (CAP): Initial report from a post-marketing phase IV surveillance trial (TeqCES)
128. Treatment of pneumococcal pneumonia: The case for penicillin G
129. Microbiological and pharmacodynamic considerations in the treatment of infection due to antimicrobial-resistant Streptococcus pneumoniae
130. In vitro killing activity of combinations of B-lactam agents with aminoglycosides against penicillin-resistant pneumococci
131. Synergy between amoxicillin and gentamicin in combination against a highly penicillin-resistant and -tolerant strain of Streptococcus pneumoniae in a mouse pneumonia model
132. Efficacy of B-lactam antibiotics combined with gentamicin against penicillin-resistant pneumococcal pneumonia in CBA/J mice
133. In vivo activity and pharmacodynamics of amoxicillin in combination with fosfomycin in fibrin clots infected with highly penicillin-resistant Streptococcus pneumoniae
134. Antibiotic therapy of community respiratory track infections: Strategies for optimal outcomes and minimized resistance emergence